By registering, you will receive our email newsletters and advertising promotions. You may unsubscribe at any time.
LAS VEGAS, NV–(Marketwired – May 09, 2016) – Cardiovascular disease is the number one cause of death in the US, taking more lives than all forms of cancer combined. Therefore, the physicians at Cenegenics Elite Health understand that testosterone replacement in deficient men not only improves quality of life, but can also be an integral part of an overall program to reduce the risk of heart attack and stroke.
While the public controversy about the potential dangers of testosterone replacement has subsided somewhat, we are still left with FDA warning labels suggesting that testosterone is likely to cause harm to patients with heart disease. This is in stark contrast to the opinion of the majority of medical experts who disagree with the FDA’s position, including the two major endocrinology societies.
There have been numerous articles refuting the studies that started the controversy. The most recent comes from The Journal of the American College of Cardiology titled “Testosterone and Cardiovascular Disease – State of the Art Review.” Among the items discussed in the review were:
To date, the FDA has refused to lift the warnings on testosterone products, despite the fact that their recommendations are not supported by the vast majority of medical literature, or by experts in the field. This is especially disconcerting when it is well known that many over the counter medications such as ibuprofen and naproxen are known to double the risk of heart attacks and stroke. These common medications are used daily by a much larger segment of the population, dwarfing the number of patients on testosterone.
For an interview or to learn more about Cenegenics’ individualized approach to reduce the risk of heart attack and stroke utilizing advanced risk assessment tools, correction of metabolic deficiencies, individualized nutrition and exercise plans along with targeted nutritional supplementation, contact Kristy Berry at [email protected].More from our newsroom